No Data
January 21 [Today's Investment Strategy]
[Fisco Selected Stocks] 【Material Stocks】 Estrast <3280> 737 yen (1/20) Engaged in the planning and sales of the condominium "Ovision Mansion" in Yamaguchi and Fukuoka. Announced that the Financial Estimates for the year-end Dividends for the fiscal year ending February 2025 are expected to be 14 yen. The previous estimate was 12 yen, and the year-end Dividends for the previous fiscal year were 11 yen. Annual Dividends will be 26 yen. The previous estimate was 24 yen, and the annual Dividends for the previous fiscal year were 22 yen. Aiming to achieve stable profit returns to Shareholders with management mindful of capital costs and stock prices.
Estlast continues to rise for three consecutive days, increasing the Financial Estimates for the year-end Dividends for the period ending in February 2025.
EstraTrust <3280.T> has continued to rise for three days, fluctuating around unchanged, reaching a temporary high of 17 yen at 754 yen. After the market close on the 20th, it was announced that the Financial Estimates for the fiscal year ending in February 2025 will be increased, which was seen as material. The Financial Estimates for the year-end dividend have been raised from the previous 12 yen to 14 yen (the previous period's actual was 11 yen). Combined with the 12 yen at the end of the second quarter (the same as 11 yen), the expected annual dividend will be 26 yen (the same as 22 yen). The company is considering the realization of stable profit returns to Shareholders with an awareness of capital costs and stock prices.
Focus on Sanjyu Construction and Sumitomo Pharma.
Yesterday, on the 20th, the U.S. stock market was closed for the Martin Luther King Jr. Day holiday, and the exchange rate was 1 dollar = 155.60-70 yen. In today's Tokyo market, Marusan Securities <8613> announced its summary of cumulative third-quarter earnings, expecting operating profit to increase by 36.2%. Mitsui Construction <1821> announced that it would raise the lower limit of its self-capital dividend rate (DOE) for the next medium-term management plan period (FY25-FY27) to 4%, up from 3% for FY22-FY24. Johnson & Johnson and the long-acting atypical antipsychotic 'Zep.'
PTS focus points for the 20th = Inspec, Tri-Eyes, Estlast, ETC.
▽ Inspec <6656.T> received a repeat order for a large order acquired in April 2021 for roll-to-roll inspection equipment. ▽ Tryeyes <4840.T> seems to have consolidated operating profit and loss for the fiscal year ending December 2024 to be break-even (previous estimate was a loss of 0.6 billion yen, while the previous year was a loss of 0.1 billion yen). This is due to the sale of newly generated A-REIT ETF with high profitability. ▽ Zain <6769.T> reported an increase in consolidated recurring profit for the fiscal year ending December 2024 due to the recognition of evaluation gains on foreign currency-denominated Assets.
STrust: Notice regarding revisions (dividend increases) to the dividend forecast for the fiscal year ending February 2025
STrust Raises FY Dividend Plan to Y26.00